-
-
-
-
-
-
-
Arrowhead licenses liver disease drug to Madrigal for $25 million upfront
-
-
-
-
-
-
-
Leerink Partners on Arrowhead Pharma (ARWR): SRPT data drives shares up despite IONS pricing update
-
-
-
-
-
-
-
Arrowhead Pharma (ARWR) Reiterated at Overweight by Cantor Fitzgerald
-
-
-
-
-
-
-
Goldman Sachs Reiterates Neutral Rating on Arrowhead Pharma (ARWR)
-
-
-
-
-
-
-
TD Cowen on Biotechnology: '10+ Potential "Thome Run" Catalysts To Watch In 2026'
-
-
-
-
-
-
-
TD Cowen on Arrowhead Pharma (ARWR): 'Momentum Is Strong; Buy'
-
-
-
-
-
-
-
Arrowhead Pharmaceuticals Inc. (ARWR) halted, news pending
-
425,556 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

